<SEC-DOCUMENT>0001125345-21-000034.txt : 20210225
<SEC-HEADER>0001125345-21-000034.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225160438
ACCESSION NUMBER:		0001125345-21-000034
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210225
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		21680202

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mgnx-20210225.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:e7d10783-62c6-4dcc-9a35-cd1024e7953a,g:371c0c63-028f-45e8-98ad-2afce1938de3,d:71458d2754dd4eb0b49b68f6406153d4--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20210225</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF80L2ZyYWc6OWU5ZTY4YjkxNjRlNDM1M2IyZTE3OWI4ZDMyNzU0MzgvdGFibGU6OTRjYmI5ZGRmYzMwNDU2YmIxMjYwYWVmYzJmZWIyMzEvdGFibGVyYW5nZTo5NGNiYjlkZGZjMzA0NTZiYjEyNjBhZWZjMmZlYjIzMV8yLTEtMS0xLTA_46c6444d-2e28-4243-93df-ae1e04db0b7b">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF80L2ZyYWc6OWU5ZTY4YjkxNjRlNDM1M2IyZTE3OWI4ZDMyNzU0MzgvdGFibGU6OTRjYmI5ZGRmYzMwNDU2YmIxMjYwYWVmYzJmZWIyMzEvdGFibGVyYW5nZTo5NGNiYjlkZGZjMzA0NTZiYjEyNjBhZWZjMmZlYjIzMV8zLTEtMS0xLTA_baea8456-6d17-4d7c-ad95-d764647a42ef">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20210225.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-16</xbrli:startDate><xbrli:endDate>2020-06-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i71458d2754dd4eb0b49b68f6406153d4_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ4_0ca36634-2400-4117-81cc-418049c3459b">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18yMzI_7543d88c-9c13-4142-8353-4761f0ba9134">February 25, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQy_38fa0c30-a8e7-4683-93d6-b99adb8327a3">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Exact Name of Registrant as Specified in Charter)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.948%"><tr><td style="width:1.0%"></td><td style="width:18.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV8wLTAtMS0xLTA_f73cc7bb-53c9-44a1-958f-89192a7941a6">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV8wLTMtMS0xLTA_12d65910-e369-4650-8c13-b3bde83020d4">001-36112</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV8wLTUtMS0xLTA_a5297d87-6269-48f0-ad7b-3e4fbed41412">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV8zLTAtMS0xLTA_369f806d-19b7-4075-92f4-e3125b365baf">9704 Medical Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV80LTAtMS0xLTA_775f11bd-0e55-4ef2-9200-b3cdbb81890b">Rockville,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV80LTEtMS0xLTA_5c60fb05-8ad1-47b0-ba4f-98f289365caa">Maryland</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV80LTMtMS0xLTA_b61899b5-3582-463d-aa3d-81eda77d9448">20850</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code:&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQz_3da1a83a-e086-4160-aee6-5862c88acb78">301</ix:nonNumeric>) <ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ5_4471ee6c-3321-4bed-b998-941fdff79e4f">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;padding-right:15.75pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6NTc1M2JlNmQ2Mjg3NDVhYTliOGE1NmQ0ODk2YTE5NDYvdGFibGVyYW5nZTo1NzUzYmU2ZDYyODc0NWFhOWI4YTU2ZDQ4OTZhMTk0Nl8xLTAtMS0xLTA_36bbd5bb-8a65-48e5-a187-54cb4c61cf10">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6NTc1M2JlNmQ2Mjg3NDVhYTliOGE1NmQ0ODk2YTE5NDYvdGFibGVyYW5nZTo1NzUzYmU2ZDYyODc0NWFhOWI4YTU2ZDQ4OTZhMTk0Nl8xLTEtMS0xLTA_eb022bc3-d7e9-4933-9c41-43e81232cea0">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6NTc1M2JlNmQ2Mjg3NDVhYTliOGE1NmQ0ODk2YTE5NDYvdGFibGVyYW5nZTo1NzUzYmU2ZDYyODc0NWFhOWI4YTU2ZDQ4OTZhMTk0Nl8xLTItMS0xLTA_deecfac4-0695-4355-b349-ea1ce27aed5b">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ0_b196dbdd-5302-449b-8668-290bc59edccf">&#9744;</ix:nonNumeric> Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ1_2822db6b-4c8a-4c85-9f8d-896ba14a760e">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ2_ecd9cf89-99ed-4b05-a99a-3dbecea4da9a">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ3_47e6dc33-23ec-4e75-a144-95264e8aea0a">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjUw_287d9bda-b685-4642-a8bd-d8dbca345abe">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i71458d2754dd4eb0b49b68f6406153d4_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations and Financial Condition</span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;25, 2021, the Company announced financial and operating results as of and for the year ended December&#160;31, 2020. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div id="i71458d2754dd4eb0b49b68f6406153d4_10"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:16.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(d)     Exhibits.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a8-kq42020exhibit991.htm">99.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a8-kq42020exhibit991.htm">Press Release dated February 25, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i71458d2754dd4eb0b49b68f6406153d4_13"></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.032%"><tr><td style="width:1.0%"></td><td style="width:44.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  February&#160;25, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President and General Counsel</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a8-kq42020exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3eb044be27cc4af69367e3cfd3dc2d70_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="image1.jpg" src="image1.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:138px"></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">MacroGenics Provides Update on Corporate Progress and 2020 Financial Results</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13pt">MARGENZA&#8482; approved in December 2020&#59; commercial launch expected March 2021</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:135%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:135%;padding-left:13pt">July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumab</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:135%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:135%;padding-left:13pt">Multiple clinical updates across portfolio anticipated in 2021</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:135%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:135%;padding-left:13pt">Conference call scheduled for today at&#160;4&#58;30 p.m. ET.</font></div><div style="padding-left:42pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ROCKVILLE, MD, February&#160;25, 2021 </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(GLOBE NEWSWIRE) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211; MacroGenics, Inc. (NASDAQ&#58; MGNX), a b</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> December&#160;31, 2020.</font></div><div style="margin-bottom:16.5pt;margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Following the approval in late 2020 of our first drug with the&#8239;U.S. Food and Drug Administration (FDA), 2021 has the potential to be another transformative year for&#8239;MacroGenics. We expect to launch MARGENZA in the coming weeks and will continue to advance our deep pipeline of promising product candidates in multiple clinical trials,&#34; said&#8239;Scott Koenig, M.D., Ph.D., President and CEO of&#8239;MacroGenics. &#8220;We are particularly excited about our ongoing, potentially registration-enabling studies, including flotetuzumab in acute myeloid leukemia (AML) and margetuximab in gastric cancer, as well as two Prescription Drug User Fee Act (PDUFA) target action dates in July related to retifanlimab and teplizumab. And finally, we look forward to providing clinical updates on multiple, ongoing dose expansion studies this year.&#8221;</font></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Key Updates on Proprietary Programs</font></div><div style="margin-bottom:9pt;margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Recent progress and anticipated events in 2021 related to MacroGenics&#8217; approved and investigational product candidates in clinical development, as well as an advanced preclinical program, are highlighted below.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">Margetuximab&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is an Fc-engineered, monoclonal antibody (mAb) that targets the HER2 oncoprotein, which is expressed by certain breast, gastroesophageal and other solid tumor cells.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.25pt">MARGENZA (margetuximab-cmkb) approval and commercial launch.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;In December 2020, the FDA approved MARGENZA in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. The launch, which is being coordinated with MacroGenics&#8217; commercial partner, EVERSANA, is expected in March.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.25pt">Phase 2&#47;3 MAHOGANY study in advanced gastric (GC) and gastroesophageal junction (GEJ) cancer.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160; The MAHOGANY clinical program contains two modules designed to evaluate margetuximab as an investigational agent in combination with a checkpoint inhibitor, with or without chemotherapy, as a potential first-line treatment for patients with advanced or metastatic HER2-positive GC&#47;GEJ. Initial safety and efficacy data from among the first 40 patients enrolled in Module A, which is evaluating margetuximab in </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">combination with retifanlimab (an anti-PD-1 therapy), are expected in the first half of 2021. Enrollment in Module B, which is evaluating margetuximab plus MacroGenics&#8217; checkpoint inhibitor molecules in combination with chemotherapy compared to standard of care therapy of trastuzumab with chemotherapy in patients with HER2-positive tumors irrespective of PD-L1 expression, is currently ongoing in coordination with the Company's regional partner in Greater China, Zai Lab.</font></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">Flotetuzumab</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;is a bispecific CD123 </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#215;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> CD3 DART&#174; molecule being evaluated in patients with primary induction failure (PIF) and early relapsed (less than six months, or ER6) AML.&#160;Six clinical and preclinical abstracts related to AML and flotetuzumab were presented at the American Society of Hematology (ASH) Annual Meeting &#38; Exposition in December 2020. MacroGenics is conducting a single-arm, registration-enabling clinical study to evaluate flotetuzumab in up to 200 patients with PIF&#47;ER6 AML, with complete remission (CR) and CR with partial hematological recovery (CRh) as the composite primary endpoint. The Company anticipates providing further updates on the clinical development of flotetuzumab in the second half of 2021, and completing full enrollment of this study in 2022.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">MGC018</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is an antibody-drug conjugate that targets B7-H3. MacroGenics continues to enroll patients with metastatic castration-resistant prostate cancer (mCRPC), triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) in the dose expansion portion of the Phase 1 clinical study. The Company expects to provide an update on this study in mid-2021.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">Enoblituzumab</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;is an Fc&#8208;engineered, anti&#8208;B7&#8208;H3 mAb. In the coming weeks, MacroGenics&#160;expects to initiate a Phase 2 study of enoblituzumab in a chemo-free regimen in combination with retifanlimab in front-line patients with squamous cell carcinoma of the head and neck (SCCHN) who are PD-L1 positive and with tebotelimab in SCCHN patients who are PD-L1 negative.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">Tebotelimab</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;is a bispecific, tetravalent DART molecule targeting PD-1 and LAG-3. Tebotelimab is being evaluated in a Phase 1 dose expansion study as monotherapy in several tumor types. An oral presentation of tebotelimab Phase 1 data in patients with relapsed&#47;refractory diffuse large B-cell lymphoma (DLBCL) was made at ASH in December 2020. In addition, data from the combination study of tebotelimab and margetuximab in patients with advanced HER2+ neoplasms were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2020. MacroGenics&#8217; regional partner in Greater China, Zai Lab, is also evaluating tebotelimab in Phase 1 combination studies with niraparib and brivanib for the study of advanced gastric cancer and hepatocellular carcinoma, respectively, as well as a monotherapy study in patients with melanoma.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics expects to provide clinical updates on tebotelimab in 2021, including future development plans. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">MGD019</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is a bispecific, tetravalent DART molecule targeting PD-1 and CTLA-4. The Company is enrolling Phase 1 dose expansion cohorts, initially in patients with microsatellite stable colorectal cancer (MSS CRC) and checkpoint-na&#239;ve NSCLC at the recommended Phase 2 dose. The Company expects to provide a clinical update on this study in mid-2021.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">IMGC936</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is an antibody-drug conjugate that targets ADAM9, a cell surface protein over-expressed in several solid tumor types. IMGC936 is being advanced under a co-development agreement with ImmunoGen, Inc. Under the 50&#47;50 collaboration, ImmunoGen is leading clinical development and the Phase 1 dose escalation study is currently enrolling patients with select advanced solid tumors.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">MGD024</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is a next-generation, bispecific CD123 &#215; CD3 DART molecule in preclinical development. The molecule incorporates a CD3 component designed to minimize cytokine-release syndrome, while maintaining anti-tumor cytolytic activity, along with an Fc domain to </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">permit intermittent dosing through a longer half-life. The Company anticipates submitting an Investigational New Drug (IND) application to the FDA by the end of 2021.</font></div><div style="margin-bottom:9pt;margin-top:8pt"><font><br></font></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Key Partnered Programs Update</font></div><div style="margin-bottom:9pt;margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Recent progress and disclosed priorities for MacroGenics&#8217; partnerered investigational molecules are highlighted below.</font></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">Retifanlimab</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;is an anti-PD-1 mAb that has been exclusively licensed to&#160;Incyte Corporation. To date, MacroGenics has earned $65 million in milestones related to retifanlimab, triggered by advancement of the molecule through various clinical and regulatory activities. In January 2021, Incyte announced that the FDA had accepted for Priority Review its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. The PDUFA target action date for retifanlimab is July 25, 2021. MacroGenics is eligible to receive up to a total of $685 million in potential remaining development, regulatory and commercial milestones. If retifanlimab is approved and commercialized, MacroGenics would be eligible to receive royalties, tiered from 15 to 24 percent, on future worldwide net sales of the drug.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">Teplizumab</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is a mAb being developed by Provention Bio, Inc. for the treatment of type 1 diabetes. In January 2021, Provention announced the FDA filing of a BLA and Priority Review for this molecule, with a PDUFA target action date of July 2, 2021. In 2018, MacroGenics sold its interest in teplizumab to Provention and is eligible to receive up to $170 million upon the achievement of certain regulatory approval milestones, including $60 million upon approval of a BLA in the U.S., additional milestone payments totaling $225 million upon the achievement of certain sales milestones and single-digit royalties on net sales of the molecule.</font></div><div style="margin-bottom:9pt;margin-top:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate Updates</font></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Janssen Collaboration. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2020, MacroGenics announced a research collaboration and global license agreement to develop a preclinical bispecific molecule with&#160;Janssen Biotech, Inc.&#160;The research collaboration will incorporate&#160;MacroGenics'&#160;proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the agreement, Janssen paid&#160;MacroGenics&#160;an upfront payment of&#160;$20 million&#160;and will be responsible for funding all expenses.&#160;MacroGenics&#160;will also be eligible to receive up to&#160;$312 million&#160;in potential milestone payments and tiered royalties on worldwide product sales.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Ms. Federica O&#8217;Brien Added to Board.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;MacroGenics recently announced the appointment of Federica &#8220;Freddi&#8221; O&#8217;Brien, a veteran executive with 25 years of financial and operational leadership in biopharmaceutical, medical device, and technology companies, to its Board of Directors.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2020 Financial Results</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cash Position</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Cash, cash equivalents and marketable securities as of December&#160;31, 2020 were $272.5 million, compared to $215.8 million as of December&#160;31, 2019. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Revenue</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Total revenue, consisting primarily of revenue from collaborative agreements, was $104.9 million for the year ended December&#160;31, 2020, compared to $64.2 million for the year ended December&#160;31, 2019. This increase was primarily due to the recognition of milestones, partially offset by timing of revenue recognition under the Company's collaborative agreements.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">R&#38;D Expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Research and development expenses were $193.2 million for the year ended December&#160;31, 2020, compared to $195.3 million for the year ended December&#160;31, 2019. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">G&#38;A Expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; General and administrative expenses were $42.7 million for the year ended December&#160;31, 2020, compared to $46.1 million for the year ended December&#160;31, 2019. This decrease was primarily due to a decrease in external costs, including consulting.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Net Loss</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Net loss was $129.7 million for the year ended December&#160;31, 2020, compared to net loss of $151.8 million for the year ended December&#160;31, 2019.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Shares Outstanding</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Shares outstanding as of December&#160;31, 2020 were 56,244,771.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Cash Runway Guidance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics anticipates that its cash, cash equivalents and marketable securities as of December&#160;31, 2020, as well as anticipated and potential collaboration payments, should enable it to fund its operations into 2023, assuming the Company&#8217;s programs and collaborations advance as currently contemplated.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call Information</font></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics&#160;will host a conference call today at&#160;4&#58;30 pm (ET)&#160;to discuss financial results for the year ended&#160;December 31, 2020&#160;and provide a corporate update. To participate in the conference call, please dial (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and provide the Conference ID&#58; 6094343.</font></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The listen-only webcast of the conference call can be accessed under &#34;Events &#38; Presentations&#34; in the Investor Relations section of the Company's website at&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;ir.macrogenics.com&#47;events.cfm</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.</font></div><div><font><br></font></div><div id="i3eb044be27cc4af69367e3cfd3dc2d70_4"></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SELECTED CONSOLIDATED BALANCE SHEET DATA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,531&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,756&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,743&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,501&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,382&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,853&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,884&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,628&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i3eb044be27cc4af69367e3cfd3dc2d70_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">97,764&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62,024&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58,644&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenue from government agreements</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,119&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,164&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,477&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104,883&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64,188&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">60,121&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">193,201&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">195,309&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">190,827&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42,742&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,064&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">235,943&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">241,373&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">231,327&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(131,060)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(177,185)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(171,206)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,321&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,374&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(247)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(129,739)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(151,811)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(171,453)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive loss&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(23)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(129,762)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(151,792)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(171,395)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.47)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.19)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic and diluted weighted average number of common shares</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,442,389&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">48,082,728&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40,925,318&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i3eb044be27cc4af69367e3cfd3dc2d70_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IMPORTANT SAFETY INFORMATION - MARGENZA</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BOXED WARNING&#58; LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.5pt">Left Ventricular Dysfunction&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MARGENZA may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue MARGENZA treatment for a confirmed clinically significant decrease in left ventricular function.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.5pt">Embryo-Fetal Toxicity&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exposure to MARGENZA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WARNINGS &#38; PRECAUTIONS&#58;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Left Ventricular Dysfunction</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Left ventricular cardiac dysfunction can occur with MARGENZA.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">MARGENZA has not been studied in patients with a pretreatment LVEF value of &#60;50%, a prior history of myocardial infarction or unstable angina within 6 months, or congestive heart failure NYHA class II-IV.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Withhold MARGENZA for &#8805;16% absolute decrease in LVEF from pre-treatment values or LVEF below institutional limits of normal (or 50% if no limits available) and &#8805;10% absolute decrease in LVEF from pretreatment values.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Permanently discontinue MARGENZA if LVEF decline persists greater than 8 weeks, or dosing is interrupted more than 3 times due to LVEF decline.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluate cardiac function within 4 weeks prior to and every 3 months during and upon completion of treatment. Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Monitor cardiac function every 4 weeks if MARGENZA is withheld for significant left ventricular cardiac dysfunction.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Embryo-Fetal Toxicity</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Based on findings in animals and mechanism of action, MARGENZA can cause fetal harm when administered to a pregnant woman. Post-marketing studies of other HER-2 directed antibodies during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Verify pregnancy status of women of reproductive potential prior to initiation of MARGENZA.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advise pregnant women and women of reproductive potential that exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in fetal harm.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advise women of reproductive potential to use effective contraception during treatment and for 4 months following the last dose of MARGENZA.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Infusion-Related Reactions (IRRs)</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">MARGENZA can cause IRRs. Symptoms may include fever, chills, arthralgia, cough, dizziness, fatigue, nausea, vomiting, headache, diaphoresis, tachycardia, hypotension, pruritus, rash, urticaria, and dyspnea.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Monitor patients during and after MARGENZA infusion. Have medications and emergency equipment to treat IRRs available for immediate use.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">In patients experiencing mild or moderate IRRs, decrease rate of infusion and consider premedications, including antihistamines, corticosteroids, and antipyretics. Monitor patients until symptoms completely resolve.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with supportive medical therapy as needed. Permanently discontinue MARGENZA in all patients with severe or life-threatening IRRs.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MOST COMMON ADVERSE REACTIONS&#58;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The most common adverse drug reactions (&#8805;10%) with MARGENZA in combination with chemotherapy are fatigue&#47;asthenia, nausea, diarrhea, vomiting, constipation, headache, pyrexia, alopecia, abdominal pain, peripheral neuropathy, arthralgia&#47;myalgia, cough, decreased appetite, dyspnea, infusion-related reactions, palmar-plantar erythrodysesthesia, and extremity pain.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov&#47;medwatch or to MacroGenics at (844)-MED-MGNX (844-633-6469).</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Link to full Prescribing Information, including Boxed Warning</font></div><div style="margin-bottom:9pt;margin-top:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About&#160;MacroGenics, Inc.</font></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.</font></div><div style="margin-bottom:9pt;margin-top:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cautionary Note on Forward-Looking Statements</font></div><div style="margin-bottom:9pt;margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, commercial prospects of or product revenues from MARGENZA, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and other statements containing the words &#34;subject to&#34;, &#34;believe&#34;, &#34;anticipate&#34;, &#34;plan&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;estimate&#34;, &#34;project&#34;, &#34;may&#34;, &#34;will&#34;, &#34;should&#34;, </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;would&#34;, &#34;could&#34;, &#34;can&#34;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including&#58; risks that MARGENZA revenue, expenses and costs may not be as expected, risks relating to MARGENZA&#8217;s market acceptance, competition, reimbursement and regulatory actions, the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.</font></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">###</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTACTS&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jim Karrels, Senior Vice President, CFO</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1-301-251-5172</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">info&#64;macrogenics.com</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mgnx-20210225.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e7d10783-62c6-4dcc-9a35-cd1024e7953a,g:371c0c63-028f-45e8-98ad-2afce1938de3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20210225" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20210225">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210225_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210225_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210225_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210225_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://macrogenics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>mgnx-20210225_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e7d10783-62c6-4dcc-9a35-cd1024e7953a,g:371c0c63-028f-45e8-98ad-2afce1938de3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/Cover" xlink:type="simple" xlink:href="mgnx-20210225.xsd#Cover"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/Cover" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>mgnx-20210225_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e7d10783-62c6-4dcc-9a35-cd1024e7953a,g:371c0c63-028f-45e8-98ad-2afce1938de3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/Cover" xlink:type="simple" xlink:href="mgnx-20210225.xsd#Cover"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/Cover" xlink:type="extended" id="ic7b3759c01df4d8f83ef7e8e236afd41_Cover"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mgnx-20210225_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e7d10783-62c6-4dcc-9a35-cd1024e7953a,g:371c0c63-028f-45e8-98ad-2afce1938de3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_1286f58e-2f60-42bf-9e6b-ed2e461902bd_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ff72e5f7-7371-44d4-b716-7263bfe8be39_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_13ce57c3-881a-4afa-b1ca-ff80a9008ef0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4e28be87-ecc4-41df-92d6-3f6cccf6b860_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_4d5bd8e9-29d4-4747-a889-38c87ba43b6f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c339e3dd-688d-479f-977d-6515fbdde496_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c9aa64ff-4e43-4dfe-b447-a5c3215e3969_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9ea73504-eb25-4633-bd29-064a6226f77f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5bc3c274-f0a0-47cb-a101-07e397fe2d3b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4fff4ca6-f9db-4931-bb17-96dd1130ecab_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_23cc2dca-71b6-43e4-b448-ccef4f3dd35b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f269e3ef-7005-4dba-99ec-bd3376c5439f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b9c08653-6e75-48b9-847c-cfc7adfb6964_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f9c785ad-a19c-4be7-81be-4aeb49f65be5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cd2cf428-7e16-4ac8-9bcd-dd2eaff51303_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ee046afa-efa6-405c-b552-78cccba234ba_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2d44cf7d-9469-4d0e-b94d-96e27e015728_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_04d9cb0b-cbd3-4255-9f36-a9fa735d7c1b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_ca0812b5-535d-4a7a-a099-d8e5f7cbee98_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b7e4263e-0ddb-4d5d-bc4a-37cd014248a5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3f8e4816-7c94-41c4-a42f-b8216cb0f09c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_178a226c-488f-4109-b2ce-cea640e5206c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mgnx-20210225_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e7d10783-62c6-4dcc-9a35-cd1024e7953a,g:371c0c63-028f-45e8-98ad-2afce1938de3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/Cover" xlink:type="simple" xlink:href="mgnx-20210225.xsd#Cover"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_63b5823d-8305-40e2-a32d-0b3b408c0eec" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_DocumentType_63b5823d-8305-40e2-a32d-0b3b408c0eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_29298669-eb85-4d0c-92b2-35fbc8935930" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_DocumentPeriodEndDate_29298669-eb85-4d0c-92b2-35fbc8935930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_213ae32f-f770-4ba5-b9ba-a7b2111fb268" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_EntityRegistrantName_213ae32f-f770-4ba5-b9ba-a7b2111fb268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_28e23855-3f7b-49cf-8ce5-dbd2b6daf83a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_28e23855-3f7b-49cf-8ce5-dbd2b6daf83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f2cd54f0-fcb6-4e64-9e8f-9f02f4c526df" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_EntityFileNumber_f2cd54f0-fcb6-4e64-9e8f-9f02f4c526df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e0ccb919-e50b-4a6c-bca0-fae358cf8fef" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_EntityTaxIdentificationNumber_e0ccb919-e50b-4a6c-bca0-fae358cf8fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1c893cbe-f10f-4faa-9877-d3c33bccc5e3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_EntityAddressAddressLine1_1c893cbe-f10f-4faa-9877-d3c33bccc5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c34b7382-284b-4e49-806c-c0acca4192f5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_EntityAddressCityOrTown_c34b7382-284b-4e49-806c-c0acca4192f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6e0264e2-c79f-40d4-abc3-41979577e343" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_EntityAddressStateOrProvince_6e0264e2-c79f-40d4-abc3-41979577e343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_16ceb0f5-2271-4a67-bd0d-c6f05f63efd8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_EntityAddressPostalZipCode_16ceb0f5-2271-4a67-bd0d-c6f05f63efd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ceb3ec74-399d-405b-b78e-4f52702d0504" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_CityAreaCode_ceb3ec74-399d-405b-b78e-4f52702d0504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_559dc35a-cbcd-472a-aec3-ee39486ee932" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_LocalPhoneNumber_559dc35a-cbcd-472a-aec3-ee39486ee932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1295528c-43c5-4669-93b1-6dfec11bd644" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_Security12bTitle_1295528c-43c5-4669-93b1-6dfec11bd644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d5421b42-3400-4d63-b221-114df106b4a9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_TradingSymbol_d5421b42-3400-4d63-b221-114df106b4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6ec92121-a05a-4f58-9d61-0f43ce30fc79" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_SecurityExchangeName_6ec92121-a05a-4f58-9d61-0f43ce30fc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e32e3322-b44a-40a3-8b87-2f4192a4856b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_WrittenCommunications_e32e3322-b44a-40a3-8b87-2f4192a4856b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_fc74444d-04a9-420a-a9fa-3bbf3ecf4e71" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_SolicitingMaterial_fc74444d-04a9-420a-a9fa-3bbf3ecf4e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c84659c7-e82b-45a1-b2aa-4dca0f386daa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_PreCommencementTenderOffer_c84659c7-e82b-45a1-b2aa-4dca0f386daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_7afe509e-66c6-4c0b-ae63-e346262bdc51" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_7afe509e-66c6-4c0b-ae63-e346262bdc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ada6e39b-2da9-432c-9cd9-d5b29fdeb42a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_EntityEmergingGrowthCompany_ada6e39b-2da9-432c-9cd9-d5b29fdeb42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_723951a4-8f17-46d8-afe8-bd240263a60f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_EntityCentralIndexKey_723951a4-8f17-46d8-afe8-bd240263a60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_04253b5e-0f85-49f1-bb6f-62cae097f146" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_048173c0-87bd-47c3-bc64-7759059d8ef1" xlink:to="loc_dei_AmendmentFlag_04253b5e-0f85-49f1-bb6f-62cae097f146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
MB5!.1PT*&@H    -24A$4@   (H   !-" 8   !Y:OQH   @ $E$051X >U]
M!WA<U;6N;R[-LB59<L'&A)  *1":*4E>N"^45. %$])N\H!K6>XVIB24=X%
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M,(HOTI+!25/'P0MVGY'GG(.MUCJL6)&-5:O67'2[Y+.8#H5"Z.[N9L,0I5$
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M=R$2(D..E#+I?,!;NQ+>G(FPYW\']MHW(!3<@8!V'.R%/T$DV,J4-Z6/>$[
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M150N_34J,I)0G<7+)D.WXJD;8)F7ANHE]Z*_90LJ_G(SRC+2$HQ9-ZJ6/L*
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MI@<0Y^6M8@:L*D>/@P>4=9WA/24^"RB*8AUN&H4$$0S2JW5W,N<:&;!KUQ:
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>mgnx-20210225_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20210225.xsd" xlink:type="simple"/>
    <context id="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-06-16</startDate>
            <endDate>2020-06-16</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF80L2ZyYWc6OWU5ZTY4YjkxNjRlNDM1M2IyZTE3OWI4ZDMyNzU0MzgvdGFibGU6OTRjYmI5ZGRmYzMwNDU2YmIxMjYwYWVmYzJmZWIyMzEvdGFibGVyYW5nZTo5NGNiYjlkZGZjMzA0NTZiYjEyNjBhZWZjMmZlYjIzMV8yLTEtMS0xLTA_46c6444d-2e28-4243-93df-ae1e04db0b7b">0001125345</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF80L2ZyYWc6OWU5ZTY4YjkxNjRlNDM1M2IyZTE3OWI4ZDMyNzU0MzgvdGFibGU6OTRjYmI5ZGRmYzMwNDU2YmIxMjYwYWVmYzJmZWIyMzEvdGFibGVyYW5nZTo5NGNiYjlkZGZjMzA0NTZiYjEyNjBhZWZjMmZlYjIzMV8zLTEtMS0xLTA_baea8456-6d17-4d7c-ad95-d764647a42ef">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ4_0ca36634-2400-4117-81cc-418049c3459b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18yMzI_7543d88c-9c13-4142-8353-4761f0ba9134">2021-02-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQy_38fa0c30-a8e7-4683-93d6-b99adb8327a3">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV8wLTAtMS0xLTA_f73cc7bb-53c9-44a1-958f-89192a7941a6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV8wLTMtMS0xLTA_12d65910-e369-4650-8c13-b3bde83020d4">001-36112</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV8wLTUtMS0xLTA_a5297d87-6269-48f0-ad7b-3e4fbed41412">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV8zLTAtMS0xLTA_369f806d-19b7-4075-92f4-e3125b365baf">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV80LTAtMS0xLTA_775f11bd-0e55-4ef2-9200-b3cdbb81890b">Rockville,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV80LTEtMS0xLTA_5c60fb05-8ad1-47b0-ba4f-98f289365caa">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6MGMwMTM3MGJiNmNjNGY0NmIzN2VmYWMwZTdjNmRmNjkvdGFibGVyYW5nZTowYzAxMzcwYmI2Y2M0ZjQ2YjM3ZWZhYzBlN2M2ZGY2OV80LTMtMS0xLTA_b61899b5-3582-463d-aa3d-81eda77d9448">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQz_3da1a83a-e086-4160-aee6-5862c88acb78">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ5_4471ee6c-3321-4bed-b998-941fdff79e4f">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6NTc1M2JlNmQ2Mjg3NDVhYTliOGE1NmQ0ODk2YTE5NDYvdGFibGVyYW5nZTo1NzUzYmU2ZDYyODc0NWFhOWI4YTU2ZDQ4OTZhMTk0Nl8xLTAtMS0xLTA_36bbd5bb-8a65-48e5-a187-54cb4c61cf10">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6NTc1M2JlNmQ2Mjg3NDVhYTliOGE1NmQ0ODk2YTE5NDYvdGFibGVyYW5nZTo1NzUzYmU2ZDYyODc0NWFhOWI4YTU2ZDQ4OTZhMTk0Nl8xLTEtMS0xLTA_eb022bc3-d7e9-4933-9c41-43e81232cea0">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGFibGU6NTc1M2JlNmQ2Mjg3NDVhYTliOGE1NmQ0ODk2YTE5NDYvdGFibGVyYW5nZTo1NzUzYmU2ZDYyODc0NWFhOWI4YTU2ZDQ4OTZhMTk0Nl8xLTItMS0xLTA_deecfac4-0695-4355-b349-ea1ce27aed5b">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ0_b196dbdd-5302-449b-8668-290bc59edccf">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ1_2822db6b-4c8a-4c85-9f8d-896ba14a760e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ2_ecd9cf89-99ed-4b05-a99a-3dbecea4da9a">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjQ3_47e6dc33-23ec-4e75-a144-95264e8aea0a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNDU4ZDI3NTRkZDRlYjBiNDliNjhmNjQwNjE1M2Q0L3NlYzo3MTQ1OGQyNzU0ZGQ0ZWIwYjQ5YjY4ZjY0MDYxNTNkNF8xL2ZyYWc6MWJkNTI5NDQxZTcwNGYxZDljMGNjYjgyZDBkODdmNGMvdGV4dHJlZ2lvbjoxYmQ1Mjk0NDFlNzA0ZjFkOWMwY2NiODJkMGQ4N2Y0Y18xNjUw_287d9bda-b685-4642-a8bd-d8dbca345abe">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140709531512184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 25,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M6)>E:H\_A?<HN9\;[O\2Q0]02P,$%     @ DX!94I>*NQS     $P(   L
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MU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ DX!94B0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ DX!94@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " "3@%E2XW9!/N\    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    ( ). 65*JQ"(6,P$  "("   /
M  "  60/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "3@%E2)!Z;HJT
M  #X 0  &@              @ '$$   >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " "3@%E299!YDAD!  #/ P  $P
M@ &I$0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #S$@
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mgnx-20210225.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mgnx-20210225.htm">mgnx-20210225.htm</File>
    <File>a8-kq42020exhibit991.htm</File>
    <File>mgnx-20210225.xsd</File>
    <File>mgnx-20210225_cal.xml</File>
    <File>mgnx-20210225_def.xml</File>
    <File>mgnx-20210225_lab.xml</File>
    <File>mgnx-20210225_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20210225.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20210225_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20210225_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20210225.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20210225_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20210225_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20210225.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20210225",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210225.htm",
      "contextRef": "i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://macrogenics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210225.htm",
      "contextRef": "i0f54a1c776fb4bfa9ce991ae5f014f95_D20200616-20200616",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001125345-21-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-21-000034-xbrl.zip
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MJUJ6U_!K1M;P0?G0%MAT@#9=%Y&%V^!>NK 0BKX3Y"R)".NN''2.$(-ZX+#
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MX"FD97AMD\4TH$Y"/"W_]*V('T'$JYTS ^,M+;RBKR9N!1B%ID'XE$3C+TF
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M%O/=%,Y1WC"-3M./P"0\E>D%R-10CS>O6YT#\ $F(%4^XR%@4\)P4F0DB%V
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MA'3,,C$*?EU0IN39()X/?@-02P,$%     @ DX!94E+MCIY;"@  HET  !4
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M27B3]PO]ZLVS]2?)\E#O-\_^#U!+ P04    " "3@%E2>>^(!ZX&  !D,0
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M?+F$H\W]F\43\4[PP,'.[1?=2[<M_V#G?U!+ 0(4 Q0    ( ). 65+)!<R
MCBH  )M* 0 8              "  0    !A."UK<30R,#(P97AH:6)I=#DY
M,2YH=&U02P$"% ,4    " "3@%E2[0T6%D,4  "O@@  $0
M@ '$*@  ;6=N>"TR,#(Q,#(R-2YH=&U02P$"% ,4    " "3@%E2.*A:_HD"
M  !T"0  $0              @ $V/P  ;6=N>"TR,#(Q,#(R-2YX<V102P$"
M% ,4    " "3@%E20")2^($!  #$ @  %0              @ 'N00  ;6=N
M>"TR,#(Q,#(R-5]C86PN>&UL4$L! A0#%     @ DX!94M7?JRH% @  :08
M !4              ( !HD,  &UG;G@M,C R,3 R,C5?9&5F+GAM;%!+ 0(4
M Q0    ( ). 65)2[8Z>6PH  *)=   5              "  =I%  !M9VYX
M+3(P,C$P,C(U7VQA8BYX;6Q02P$"% ,4    " "3@%E2>>^(!ZX&  !D,0
M%0              @ %H4   ;6=N>"TR,#(Q,#(R-5]P<F4N>&UL4$L%!@
0   '  < T $  $E7      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
